Why is Kilitch Drugs falling/rising?

As of 05-Sep, Kilitch Drugs (India) Ltd is experiencing a rise in its stock price, currently at Rs 372.75, reflecting an increase of Rs 10.3 or 2.84%. The stock has shown strong performance today, outperforming its sector by 2.91% and achieving a consecutive gain over the last five days, with a total return of 9.92% during this period. Despite a recent decline of 14.91% over the past month, the company has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 31.41% and operating profit rising by 72.48%. However, concerns regarding management efficiency, indicated by a low return on equity (ROE) of 7.27%, and flat results in the latest quarter may be weighing on investor sentiment.
In the broader market context, Kilitch Drugs has significantly outperformed the benchmark Sensex over the past week, which has only increased by 1.13%. The stock's year-to-date return stands at 15.40%, compared to the Sensex's 3.29%, and it has consistently outperformed the BSE500 over the last three years. Despite these positive indicators, the stock's liquidity is somewhat limited, with a notable decline in delivery volume, suggesting a potential decrease in investor participation. Additionally, the lack of domestic mutual fund investment may indicate hesitance among institutional investors regarding the stock's valuation and business outlook.